Semaglutide (Wegovy) is more widely covered for weight loss than tirzepatide (Zepbound) because its been approved longer
The headlines sound positive, but FDA has not approved BPC-157 or made its final decision
Rival products like Desobody or Aqualyx on the other hand, contain deoxycholic acid, which is safety tested and proven to dissolve fat cells
Novel diabetes drugs and the cardiovascular specialist
Semaglutide is designed to complement these efforts, not replace them
Most are gastrointestinal, including nausea, vomiting, diarrhea, constipation, or abdominal discomfort, but some symptoms may signal dehydration, kidney stress, gallbladder disease, pancreatitis, hypoglycemia, or another problem that requires medical evaluation